GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rangering i aksjer
#3633
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aksjekurs
$27.54
Sist synkronisert: 2026-10-19
Markedsverdi
$4.67B
Endring (1 dag)
-2.73%
Endring (1 år)
-11.86%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategori
Healthcare
EPS for GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
EPS per June 2026 TTM: $0.70
Ifølge de siste økonomiske rapportene og aksjekursen til GlaxoSmithKline Pharmaceuticals Limited er selskapets nåværende EPS (TTM) $0.70. Ved slutten av 2024 hadde selskapet en EPS på $0.42, en nedgang sammenlignet med EPS-en i 2023 som var $0.44.
EPS-historikk for GlaxoSmithKline Pharmaceuticals Limited fra 2004 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $0.70 | 8.72% |
| 2025 | $0.64 | 53.29% |
| 2024 | $0.42 | -4.31% |
| 2023 | $0.44 | 55.78% |
| 2022 | $0.28 | 20.93% |
| 2021 | $0.23 | 217.40% |
| 2020 | $0.07 | -80.72% |
| 2019 | $0.38 | 19.09% |
| 2018 | $0.32 | 3.69% |
| 2017 | $0.31 | -8.50% |
| 2016 | $0.34 | -7.07% |
| 2015 | $0.36 | -0.91% |
| 2013 | $0.36 | -39.74% |
| 2012 | $0.60 | 26.71% |
| 2011 | $0.48 | -35.63% |
| 2010 | $0.74 | 14.81% |
| 2009 | $0.64 | -10.33% |
| 2008 | $0.72 | -12.43% |
| 2007 | $0.82 | 11.92% |
| 2006 | $0.73 | 11.91% |
| 2005 | $0.66 | 47.32% |
| 2004 | $0.45 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $29.89 | 4,195.77% |
US
|
|
| $6.60 | 848.55% |
US
|
|
| $3.55 | 410.20% |
US
|
|
| $1.26 | 81.09% |
US
|
|
| $20.39 | 2,830.30% |
CH
|
